The US Food and Drug Administration has reiterated that overall survival remains the preferred primary endpoint in oncology clinical trials. While acknowledging scenarios where surrogate endpoints may be appropriate, the FDA stressed the importance of definitive outcome measures reflecting patient benefit. This statement influences the design of ongoing and future cancer drug development programs, emphasizing clinical benefit in survival and quality of life.